Metformin use is associated with a decreased incidence of colorectal adenomas in diabetic patients with previous colorectal cancer

Jin Ha Lee, Soung Min Jeon, Sung Pil Hong, Jae Hee Cheon, Tae Il Kim, Won Ho Kim

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Background: Metformin use has been associated with decreased cancer risk and mortality. However, the effects of metformin on the development of colorectal adenomas, the precursors of colorectal cancers, are not defined. Aims: This study aimed to evaluate the potential effect of metformin on the incidence of colorectal adenomas in diabetic patients with previous colorectal cancer. Methods: Among 488 consecutive diabetic patients who underwent colonoscopic surveillance after curative resection of colorectal cancer between 1998 and 2008, 240 patients were enrolled in this study and were compared in two groups: 114 patients taking metformin and 126 patients not taking metformin. Patient demographics, clinical characteristics, and colorectal adenoma incidence rate were analysed. Results: After a median follow-up of 58 months, a total of 33 patients (28.9%) exhibited adenomatous colorectal polyps among the 114 patients who used metformin, compared with 58 (46.0%) patients with colorectal adenomas among the 126 patients who did not use metformin (odds ratio = 0.48, 95% confidence interval = 0.280-0.816, P= 0.008). After adjustment for clinically relevant factors, metformin use was found to be associated with a decreased incidence of colorectal adenomas (odds ratio = 0.27, 95% confidence interval = 0.100-0.758, P= 0.012) in diabetic patients with previous colorectal cancer. Metformin use in diabetic patients with previous colorectal cancer is associated with a lower risk of colorectal adenoma.

Original languageEnglish
Pages (from-to)1042-1047
Number of pages6
JournalDigestive and Liver Disease
Volume44
Issue number12
DOIs
Publication statusPublished - 2012 Dec 1

Fingerprint

Metformin
Adenoma
Colorectal Neoplasms
Incidence
Odds Ratio
Confidence Intervals
Adenomatous Polyps
Demography

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

Lee, Jin Ha ; Jeon, Soung Min ; Hong, Sung Pil ; Cheon, Jae Hee ; Kim, Tae Il ; Kim, Won Ho. / Metformin use is associated with a decreased incidence of colorectal adenomas in diabetic patients with previous colorectal cancer. In: Digestive and Liver Disease. 2012 ; Vol. 44, No. 12. pp. 1042-1047.
@article{6e537a9cca1646fc89d0713d6b0e62aa,
title = "Metformin use is associated with a decreased incidence of colorectal adenomas in diabetic patients with previous colorectal cancer",
abstract = "Background: Metformin use has been associated with decreased cancer risk and mortality. However, the effects of metformin on the development of colorectal adenomas, the precursors of colorectal cancers, are not defined. Aims: This study aimed to evaluate the potential effect of metformin on the incidence of colorectal adenomas in diabetic patients with previous colorectal cancer. Methods: Among 488 consecutive diabetic patients who underwent colonoscopic surveillance after curative resection of colorectal cancer between 1998 and 2008, 240 patients were enrolled in this study and were compared in two groups: 114 patients taking metformin and 126 patients not taking metformin. Patient demographics, clinical characteristics, and colorectal adenoma incidence rate were analysed. Results: After a median follow-up of 58 months, a total of 33 patients (28.9{\%}) exhibited adenomatous colorectal polyps among the 114 patients who used metformin, compared with 58 (46.0{\%}) patients with colorectal adenomas among the 126 patients who did not use metformin (odds ratio = 0.48, 95{\%} confidence interval = 0.280-0.816, P= 0.008). After adjustment for clinically relevant factors, metformin use was found to be associated with a decreased incidence of colorectal adenomas (odds ratio = 0.27, 95{\%} confidence interval = 0.100-0.758, P= 0.012) in diabetic patients with previous colorectal cancer. Metformin use in diabetic patients with previous colorectal cancer is associated with a lower risk of colorectal adenoma.",
author = "Lee, {Jin Ha} and Jeon, {Soung Min} and Hong, {Sung Pil} and Cheon, {Jae Hee} and Kim, {Tae Il} and Kim, {Won Ho}",
year = "2012",
month = "12",
day = "1",
doi = "10.1016/j.dld.2012.06.007",
language = "English",
volume = "44",
pages = "1042--1047",
journal = "Digestive and Liver Disease",
issn = "1590-8658",
publisher = "Elsevier",
number = "12",

}

Metformin use is associated with a decreased incidence of colorectal adenomas in diabetic patients with previous colorectal cancer. / Lee, Jin Ha; Jeon, Soung Min; Hong, Sung Pil; Cheon, Jae Hee; Kim, Tae Il; Kim, Won Ho.

In: Digestive and Liver Disease, Vol. 44, No. 12, 01.12.2012, p. 1042-1047.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Metformin use is associated with a decreased incidence of colorectal adenomas in diabetic patients with previous colorectal cancer

AU - Lee, Jin Ha

AU - Jeon, Soung Min

AU - Hong, Sung Pil

AU - Cheon, Jae Hee

AU - Kim, Tae Il

AU - Kim, Won Ho

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Background: Metformin use has been associated with decreased cancer risk and mortality. However, the effects of metformin on the development of colorectal adenomas, the precursors of colorectal cancers, are not defined. Aims: This study aimed to evaluate the potential effect of metformin on the incidence of colorectal adenomas in diabetic patients with previous colorectal cancer. Methods: Among 488 consecutive diabetic patients who underwent colonoscopic surveillance after curative resection of colorectal cancer between 1998 and 2008, 240 patients were enrolled in this study and were compared in two groups: 114 patients taking metformin and 126 patients not taking metformin. Patient demographics, clinical characteristics, and colorectal adenoma incidence rate were analysed. Results: After a median follow-up of 58 months, a total of 33 patients (28.9%) exhibited adenomatous colorectal polyps among the 114 patients who used metformin, compared with 58 (46.0%) patients with colorectal adenomas among the 126 patients who did not use metformin (odds ratio = 0.48, 95% confidence interval = 0.280-0.816, P= 0.008). After adjustment for clinically relevant factors, metformin use was found to be associated with a decreased incidence of colorectal adenomas (odds ratio = 0.27, 95% confidence interval = 0.100-0.758, P= 0.012) in diabetic patients with previous colorectal cancer. Metformin use in diabetic patients with previous colorectal cancer is associated with a lower risk of colorectal adenoma.

AB - Background: Metformin use has been associated with decreased cancer risk and mortality. However, the effects of metformin on the development of colorectal adenomas, the precursors of colorectal cancers, are not defined. Aims: This study aimed to evaluate the potential effect of metformin on the incidence of colorectal adenomas in diabetic patients with previous colorectal cancer. Methods: Among 488 consecutive diabetic patients who underwent colonoscopic surveillance after curative resection of colorectal cancer between 1998 and 2008, 240 patients were enrolled in this study and were compared in two groups: 114 patients taking metformin and 126 patients not taking metformin. Patient demographics, clinical characteristics, and colorectal adenoma incidence rate were analysed. Results: After a median follow-up of 58 months, a total of 33 patients (28.9%) exhibited adenomatous colorectal polyps among the 114 patients who used metformin, compared with 58 (46.0%) patients with colorectal adenomas among the 126 patients who did not use metformin (odds ratio = 0.48, 95% confidence interval = 0.280-0.816, P= 0.008). After adjustment for clinically relevant factors, metformin use was found to be associated with a decreased incidence of colorectal adenomas (odds ratio = 0.27, 95% confidence interval = 0.100-0.758, P= 0.012) in diabetic patients with previous colorectal cancer. Metformin use in diabetic patients with previous colorectal cancer is associated with a lower risk of colorectal adenoma.

UR - http://www.scopus.com/inward/record.url?scp=84868302293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868302293&partnerID=8YFLogxK

U2 - 10.1016/j.dld.2012.06.007

DO - 10.1016/j.dld.2012.06.007

M3 - Article

C2 - 22789400

AN - SCOPUS:84868302293

VL - 44

SP - 1042

EP - 1047

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

SN - 1590-8658

IS - 12

ER -